Australian Competition and Consumer Commission v Homeopathy Plus! Australia Pty Ltd

Link copied
Case Copied 71 min read

FEDERAL COURT OF AUSTRALIA

Australian Competition and Consumer Commission v Homeopathy Plus! Australia Pty Limited [2014] FCA 1412

Citation: Australian Competition and Consumer Commission v Homeopathy Plus! Australia Pty Limited [2014] FCA 1412
Parties: AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v HOMEOPATHY PLUS! AUSTRALIA PTY LIMITED and FRANCES MERCIA SHEFFIELD
File number: NSD 256 of 2013
Judge: PERRY J
Date of judgment: 22 December 2014
Catchwords:

CONSUMER LAW – Whether misleading, deceptive or false representations made on website about the effectiveness of whooping cough vaccine – Means of assessing efficacy and effectiveness of vaccine – Evidence based medicine – Bearing of context on characterisation of representations – Whether representations misleading, deceptive or false when read in context of an epidemic – Whether representation that vaccine was “short-lived” was misleading, deceptive or false given vaccine’s propensity to wane over time. 

CONSUMER LAW – Whether misleading, deceptive or false representations made about the effectiveness of homeopathic treatments for the prevention of whooping cough   – Whether representations about effectiveness of homeopathic treatments fall to be assessed against a homeopathic epistemological framework or orthodox medical science – Whether representations imply a reasonable basis in medical science.

CONSUMER LAW – Whether disclaimers erase misleading, deceptive and false nature of representations – Where disclaimer did not clearly bring the true position to the public’s attention.

CONSUMER LAW – Whether representations made in trade or commerce – Whether or not carried on for profit –
Where representations said to be contribution to public debate or educational – Whether conduct has requisite commercial or trading character – Where conduct has dual character – Where representations not presented overtly in form of an advertisement.

EVIDENCE – Where expert reports do not comply with s 79 of the Evidence Act 1995 (Cth) – Precondition to admissibility of expert evidence – Failure to provide reasons for opinion and demonstrate connection with specialised knowledge – Whether the manner in which material might be presented in the field of expertise is relevant – Duty of legal representatives to ensure expert reports comply with rules of evidence and court practice directions.

Legislation:

Australian Consumer Law, ss 4, 6(3)(a),(b), 18, 29(1)(a),(b),(g)

Competition and Consumer Act 2010 (Cth) s 6
Corporations Act 2001 (Cth), ss 180, 181, 182
Evidence Act 1995 (Cth), ss 79 and 190(3)(b)
National Health and Medical Research Council Act 1992 (Cth) ss 3(1), 7(1)
Therapeutic Goods Act 1989 (Cth) ss 3(1), 4, 19, 19A, 19D(1), 19D(4), 25

Cases cited: Australian Competition and Consumer Commission v Dukemaster Pty Ltd [2009] FCA 682; [2009] ATPR 42-290
Australian Competition and Consumer Commission v Jones (No 5) [2011] FCA 49
Australian Competition and Consumer Commission v Jutsen (No 3) (2011) 206 FCR 264
Australian Competition and Consumer Commission v Kaye [2004] FCA 1363
Australian Competition and Consumer Commission v TPG Internet Pty Ltd [2013] HCA 54; (2013) 250 CLR 640
Aspen Pharmacare Australia Pty Ltd v Minister for Health and Ageing [2012] AATA 362
Butcher v Lachlan Elder Realty Pty Ltd (2004) 218 CLR 592
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Australian Competition and Consumer Commission v Homeopathy... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] FCA 1412
Decision Date

CaseChat Overview and Summary

The Australian Competition and Consumer Commission (ACCC) brought an action against Homeopathy Plus! Australia Pty Ltd in the Federal Court, alleging that the respondent had made misleading and deceptive representations about the effectiveness of the whooping cough vaccine and homeopathic treatments for whooping cough prevention. The ACCC claimed that the representations were false and misleading, and that they contravened sections 18 and 29 of the Australian Consumer Law (ACL). The court was required to determine whether the representations made by the respondent were misleading, deceptive or false, whether they were made in trade or commerce and whether they were carried on for profit. The court also had to decide whether the representations were misleading, deceptive or false when read in the context of an epidemic, and whether the disclaimers erased the misleading, deceptive and false nature of the representations.

The court found that the representations made by the respondent were misleading, deceptive or false, and that they were made in trade or commerce and carried on for profit. The court held that the representations about the effectiveness of the vaccine and homeopathic treatments for whooping cough prevention were false and misleading, and that they contravened sections 18 and 29 of the ACL. The court also found that the disclaimers did not erase the misleading, deceptive and false nature of the representations. The court held that the representations were misleading, deceptive or false when read in the context of an epidemic, and that the representations that the vaccine was "short-lived" were misleading, deceptive or false given the vaccine's propensity to wane over time. The court found that the representations about the effectiveness of homeopathic treatments for whooping cough prevention did not fall to be assessed against a homeopathic epistemological framework or orthodox medical science, and that they implied a reasonable basis in medical science.

The court held that the evidence led by the ACCC as to the nature and seriousness of whooping cough, the nature of the vaccine and recommended schedule for its administration and the essential precepts of Evidence Based Medicine were not contentious. The court held that the expert evidence led by the respondent did not comply with the rules of evidence and was therefore inadmissible. The court held that the representations made by the respondent were not contributions to public debate or educational, and that they had the requisite commercial or trading character.

The court made a declaration that the respondent had engaged in conduct in trade or commerce that was misleading and deceptive, or likely to be so, in contravention of section 18 of the ACL. The court also made a declaration that the respondent had made false or misleading representations in trade or commerce that the vaccine was of a particular standard or quality, and that homeopathic treatments were a safe and effective alternative to the vaccine. The court ordered that the matter be listed for directions to set a timetable for any further evidence on the question of penalties and submissions including on the injunctive and other final orders sought by the ACCC.

Orders

Orders of the court

3) The matter is listed for directions at 9.30 am on Wednesday 4 February 2015 in order to set a timetable for any further evidence on the question of penalties and submissions including on the injunctive and other final orders sought by the Applicant.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

In short, the reason why the evidence in question was excluded was not because it was product of, to use the words of counsel for the Respondents, a science which operates in a different paradigm from orthodox medical science. Nor was it excluded because, as the Respondents also submitted, “…automatic superiority and automatic preference [is] given to one paradigm over the other either at the admissibility level or the weight level …” The evidence was excluded because the Respondents’ evidence must comply with the same rules of evidence as those which apply to all parties under the Evidence Act, relevantly, the requirements for the admissibility of expert opinion evidence under s 79. Responsibility for ensuring that evidence is put before this court in admissible form lies with the legal representatives. It is no answer, as Lindgren J has said, to say that the expert is unaccustomed or untrained in presenting evidence in an admissible form; nor that the form in which the evidence is presented reflects the way in which material might customarily be presented within the field of expertise in question.4. Background concepts and facts The expert evidence led by the ACCC as to the nature and seriousness of whooping cough, the nature of the Vaccine and recommended schedule for its administration and the essential precepts of Evidence Based Medicine were not contentious. 4.1 Pertussis – the disease and potential complications Pertussis, otherwise known as whooping cough, can be a serious respiratory disease and is caused by the bacterium Bordetella pertussis (“pertussis”). It is an exclusively human pathogen spread by respiratory droplets. It is highly infectious, spreading to 90% of “susceptible household contacts”, being individuals who are not immune and live in the same house as the infectious person. Pertussis is known for the uncontrollable and violent paroxysms (bouts) of coughing experienced by those suffering from the disease at the end of which, the patient needs to take a deep breath resulting in a “whooping” sound. “Classical pertussis” typically has an incubation period of 7 to 10 days followed by three phases of illness: (a)The first phase is catarrhal. This is a non-specific nasal congestion illness accompanied by a mild cough, lasting one to two weeks.(b)The second phase is paroxysmal: namely, a spasmodic cough, post-cough vomiting and inspiratory whoop which lasts for four to six weeks or longer. Facial suffusion (redness/congestion) with prominent eyes and protrusion of neck veins may be seen during these paroxysms. It can also affect infant’s feeding. (c)The final phase is convalescent during which the symptoms slowly improve over one to two weeks, although the phase may persist longer. The cough may persist for a number of weeks or months and future episodes of upper respiratory tract infections may restimulate the coughing paroxysms. If untreated, a person with whooping cough is contagious for at least 21 days. Whooping cough is treated by ten day course of antibiotics, after the first five days of which there is minimal chance of transmitting the disease. This means, as Dr Crawford explained, that early treatment is an important public health measure for decreasing the risk of further contact cases. However the antibiotic treatment will not stop or improve the cough.

Evidence

Evidence Before The Court

Dr Golden is an Honorary Research Fellow at the School of Science, Information Technology and Engineering at the University of Ballarat. He holds a Doctor of Philosophy from Swinburne University of Technology awarded in 2004 on the topic of Potential value of Homeoprophylaxis in the Long-Term Prevention of Infectious Diseases and the Maintenance of General Health in Recipients, together with diplomas in naturopathy and homoeopathy from the Melbourne College of Naturopathy in 1990 and the Melbourne College of Homoeopathy in 1989 respectively. To the extent that Dr Golden’s report was admitted, it was largely confined by orders under s 136 of the Evidence Act to a description of the philosophical approach of homeopathy to the treatment and prevention of disease as opposed to evidence on the effectiveness of homeopathy in preventing whooping cough. The closing submissions for the Respondents repeatedly overlooked the limited basis on which Dr Golden’s evidence was admitted, submitting that it showed that there is a reasonable basis in homeopathic science for the representations about homeoprophylaxis. However, given the terms of the order, his evidence simply could not be put to that use. 3.2 Admissibility of expert opinion evidence under the Evidence Act Given the extent of the apparent difficulties with the Respondents’ expert evidence and the potential impact of excluding such evidence upon the Respondents’ case, I delivered detailed reasons in the course of the trial for ruling inadmissible sample passages from the report of Dr Golden. It is helpful to repeat the substance of those reasons here. These reasons were illustrative of the difficulties found in the bulk of the Respondents’ expert reports. By s 76(1) of the Evidence Act, the general rule is that “evidence of an opinion is not admissible to prove the existence of a fact about the existence of which the opinion was expressed”. This rule is known as the “opinion rule”. Section 79 of the Evidence Act exempts evidence of certain opinions of experts from the general rule in s 76(1) and provides that:If a person has specialised knowledge based on the person’s training, study and experience, the opinion rule [in s 76(1)] does not apply to evidence of an opinion of that person that is wholly or substantially based on that knowledge. As Lindgren J held in Harrington-Smith on behalf of the Wongatha People v Western Australia (No 2) (2003) 130 FCR 424 (“Harrington-Smith”) at 427 (an authority relied upon by the Respondents):By providing for an exception to the inadmissibility created by the opinion rule, s 79 goes to admissibility… the section poses an objective test; no discretion is involved; a party raising an objection to admissibility on the ground that the section is not satisfied is entitled to a ruling on the objection… The test which must be applied in determining whether expert opinion evidence is admissible under s 79 was considered by the High Court in Dasreef Pty Limited v Hawchar (2011) 243 CLR 588 (“Dasreef”). The joint judgment in that decision of French CJ, Gummow, Hayne, Crennan, Kiefel and Bell JJ established in my opinion the following matters.

Decision

Reasons for decision

However, I do not consider that the evidence supports the existence of any public debate about the use of homeoprophylaxis as an alternative to the vaccination for the prevention of whooping cough or generally. As the ACCC submitted, “the impugned conduct does not reasonably appear to promote or provide a contribution to, public debate concerning a current or proposed law or government policy, or another issue of general concern to the community.” Certainly Mrs Sheffield was an advocate and perhaps Dr Golden. However, there was no evidence of any widespread debate about the issue and in particular no evidence any homeopathic representative body considered that this was an issue. To the contrary, the Australian Register of Homeopaths, which is the peak body in Australia, has taken the position that homeoprophylaxis should not be recommended as a substitute for immunisation: see at [266] above. 9. CONCLUSION It follows for these reasons that I find the contraventions of ss 18 and 29 of the ACL as alleged by the ACCC to be made out. First, by publishing the Three Articles containing the Vaccine Representations and the Alternative Homeopathy Reasonable Basis Representations, the Respondents engaged in conduct in trade or commerce that was misleading and deceptive, or likely to be so, in contravention of s 18 of the ACL. Furthermore, the Respondents in trade or commence made false or misleading representations that the Vaccine is of a particular standard or quality (essentially short-lived, unreliable and ineffective) contrary to ss 29(1)(a) and (b) of the ACL by publishing the Vaccine representations in the Three Articles when in fact the Vaccine is effective in protecting the significant majority of people exposed to the infection from contracting whooping cough. Finally, the Respondents also in trade or commerce made false or misleading representations in connection with the supply or possible supply of homeopathic products or treatments that these products or treatments have a particular standard or quality, contrary to s 29(1)(a) and (b) of the ACL, and have a use or benefit contrary to s 29(1)(g), namely: that there is an adequate foundation in medical science for the statement that homeopathic treatments are a safe and effective alternative to the Vaccine when no such foundation exists and the Vaccine is the only treatment currently approved for use and accepted by medical practitioners in Australia for the prevention of whooping cough. I intimated at the end of the hearing that, if I should find a contravention, I may leave the terms of the declaratory relief to be matters for the conclusion of the case. However, in the circumstances, the terms of the draft declaratory relief sought by the ACCC simply reflect my findings. This is not a case where my findings would sustain only some, but not all, of the declaratory relief sought and where there may as a result be some room for argument as to how those findings might be reflected in the declarations. For this reason I consider it appropriate to make the declarations now in the terms sought. The parties will be heard on the question of the penalties sought by the ACCC and other final relief sought.

Ratio Decidendi

Legal Principle Established

In undertaking the balancing exercise required by s 25(1), a high level of safety is required from vaccines, which unlike most medications, are generally given to healthy people, to prevent illness and death. Dr Crawford explained that a fever in the first twenty-four hours is an expected and common side effect from the administration of a vaccine because the vaccine operates to stimulate the system to produce a new protection. 4.3 Administration of the Vaccine under the National Immunisation Program The Vaccine is administered in Australia as part of the National Immunisation Program (NIP), in common with the majority of vaccines. All of the pertussis vaccines under the NIP are acellular pertussis vaccines (“Pa”), containing three or more purified components of B.pertussis. The change from a whole cell pertussis to acellular vaccines took place in the late 1990s. The vaccine is injectable and usually given as part of a combination vaccine including diphtheria (D) and tetanus (T) (“DTPa”), and may also include hepatitis B, polio and Haemophilus influenzae type b. In line with the requirements earlier outlined, the Vaccine had to be approved as a medication by the TGA before it could be included on the NIP. Dr Crawford explained the process following TGA approval by which a vaccine is added to the NIP: The vaccine is then reviewed by the Australian Technical Advisory Group on Immunisation (ATAGI), who will make recommendations about the utility of adding a vaccine to the NIP. The vaccine then requires a cost effectiveness evaluation through the Pharmaceutical Benefits Advisory Committee (PBAC)… This assessment will take into account the efficacy/effectiveness of the vaccine on available evidence and the price proposed by the pharmaceutical company. These recommendations then go to the federal government for approval through the Department of Health in Canberra before a new vaccine can be added onto the NIP. State health departments are involved in the introduction of vaccines onto the NIP program. The pertussis vaccine is generally included in a combined vaccine administered by injection, the type of which varies depending on the recipient’s age. While pertussis vaccination schedules differ around the world, Dr Wood explained that none currently started earlier than six weeks of age. The schedule recommended by the World Health Organisation is six, ten and fourteen weeks for primary immunisation. The recommended schedule in Australia is administration of the vaccine: (a)at 6 – 8 weeks, 4 and 6 months of age (the primary schedule);with boosters at:(b)at 3.5 – 4 years; and(c)during adolescence (11 – 13 years); and(d)adulthood (recommended for those who wish to reduce the likelihood of becoming ill with pertussis, such as parents of young infants, and at 50 years of age);(collectively, “the Vaccine”: see Australian Government Department of Health and Aging, The Australian Immunisation Handbook (10th Ed, 2013) at 4.12.7 (the “Australian Immunisation Handbook”)).